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Thmbolyris of acute pulmonaq embolism can be accompllshed 
more rapidly and safely wilh MO mg of recambinan, buman 
,iEsue.,yp pbxminogan aefivator (rl.P.4) (Activate) than with 
a convadional dose of urokinnrr (Abbokinasej given as P 
4,400.IJlkg b&s dose, followed by 4,4C+l U/kg per b for 7.4 h. To 
delermine the &cts of B mot”? concentrated urokinw dose 
administered over a shorter time count, this trial enrolled 90 
patients with ba3aline perfusion lung scans and angiographieally 
documented oulmonar” anbclirm. The” were randomized to 
r&w either IW mgii b of r&PA or a novel dmiog regimen of 
ur&inaur; 3 million U12 h wilh the initial 1 million b given 6s a 
tmtur injection over 10 min. Both drugs were lrlivored thmugh a 
peripheral vein. 
an&rams at 2 h were performed in 87 patienb and then graded 
in a blinded manner b” a oanet of six investbwtors. (If the 42 
plirnts allocakd to rLPA’,herapy, 79% rhokd sngiograpbic 
improvemen, a, 2 h, compared wilh 57% of the I padents 
randomized to urokinase therapy (9.5% confidence Yewal for the 
diUennce in the% pronotions [rt.PA minw urokinaoel is -6.6% 
The resulls indiit; ihat B 2.h regimen of rt-PA and P DOW 
dosing regimen af urokbmse xhibit simiku eficacy rmd salety for 
treatment of acute pulmonary omboltsm. 
(J Ani CO,, cwdialI9Yz$oz24-3o, 
In a previous randomized controlled trial (I) comparing 
recombinant human tissue-type plasminogen activator (rt- 
PA) and urokinase for treatment of acute pulmonary embo- 
lism, we demonstrated that a IOO-mg dose of r&PA given 
over 2 h caused more rapid clot lysis and fewer bleeding 
complications than did a weight-adjusted 24-h infusion of 
urokinase approved by the Food and Drug Administration. 
We stated that further work was necessary to determine 
whether important differences existed between rt-PA and 
urokinz %?hz bo!!~ were given over the same 2-h time 
period. Several groups (2-4) amplified our cwtionary note 
regarding lack of comparability between the 2-h &PA ad 
the 24-h urokinase thrombolytic dosirg regimens. WC cow 
prerent the results of a subsequent randomized controlled 
trial in which the IOO-mg rt-PA dose was tested against B 
novel 2-h dosing regimen af 3 million U of urokinase, 
admimstered as a bolus injection of 1 milbon U wer IO min 
followed by another 1 million U as an infusion over the next 
110 min. We maintained the same two principal end points: 
improved findings in the 2-h pulmonary angiogram and 24-h 
perfusion lung sew over those obtained before treatment. 
Study patients. The study group comprised Patients St8 
years old who had angioSraphicaliy documented pulmonary 
embolism in one or more reemental or more orohima! hvdrocoflisonr ,100 ma intravenoousivl. diohcnhvdramine 
pulmonarya~eriesand who makfestednew rympt& ~14 tiS to 50 mg intraven&lyl and ac&min~phen~(6SO mg 
davs txeviooslv. Of the 92 oabents randomned. 2 did not orallv). Thev then received I million U ofurokinase throuch _. , 
receive thrcmbolytt therapy. One randomization envelope a p&pheraivein over IO min followed by 2 million U ov& 
(n-PA) was opened before the pulmonary angiogram was 110 min for a iota1 dose of 3 million U over 2 h. After 
completed; wults of the pulmonary angiogram were normal discontrcatmn of either thrombolytic awnt. hcpann was 
and une,monia was dnnnored. Airotber raodomizario~~ <II- girLi, (withoot a to!rc in+c!iz,; wbsr, the thromoin tire or 
velope (w&ruse; *as opened at acsnter:h~ had ~oadver& 
The pmtocol was approved hy the Food and Drug Ad- 
ently not iettocked its study drug. Of the 90 patients who 
underwent thrombolysis. 2 did not have 2-h pulmonary 
ministration and the Human Subjects Committee of each 
angiograms (I patient randomized tu arokmaae rherapy died 
of ventricular fibrillation while receiving the :hrombolytlc 
padcipating hospital; written informed conserd for the study 
infusion. and I patient randomized to n-PA therapy mad- 
vertently removed his femoral venous sheath after 15 min of 
was obtained from ali subjects. The trial was conducted 
treatment). Ooe follow-up angiogram (on a patient who 
received r&PA) was technically inadequate because the 
catheter was in the right atrium rather than the pulmonary 
artery. 
&al thromboplastin t& WIE less !han twice the control 
value. The average heparin dose was 1.050 Uih (range 7M) 10 
2.5001. Heparm administration ww continued. OP average. 
f”> 6.6 days. 
and quantitatwely. For the qualitatrvr assessment. paneiistr 
graded change within sets of angiogmms from a patient as 
Analyses of eftleacy. For fomml analysis. sets of pulmo- 
nary angiograms were coded and presented to a panei of SIX 
marked. moderate. slight or absent. In the quantitative 
mvestiqalors. who scored them by the system used in the 
Urokinase Pulmonary Embolism Trial (6). Without knowl- 
scoring system (6). unilateral angiogmms were graded from 0 
edge ofthe patient’s treatment or the timing of the angiogram 
selected for analysis, investigators first judged the techntcal 
adequacy of the angiogmm and then assessed it qualiL?tively 
between March 1988 and March KBI. (no clot) to 9 (massive clot). but nonocclusive filling defects 
The durbn criteria IWP: I) maior internal bleeding in segmental vessels were not distinguished from total oc- 
within the previous 6 months. 2) &acranial disease. 
or renal fun&& 8) pregnancy or b&ion, 9) inabil& to 
tolerate t!,e initial diagnostic pulmonary angiographic inves- 
3) operation or organ biopsy in the past I3 days. 4) wult 
tigation. 
blood on stool examination, 5) hematacrit <30%. 6) severe 
uncontrolled hvoertension, 71 severe mvxirment of beoatic 
Pulmonary angiography and perfusion lung seatwing. 
After baseline ventilation-perfusion lung scanning nnd mea- 
surement of right atrial, right ?entricular and pu!monary 
artery press&, selective angiography of the appropriate 
(right or left) pulmonary artery was performed. When pul- 
monary embolism was detected in a segmental or more 
proximal polmonary arLe:ery, lhe patient was randomized to 
&PA or urokinase therapy by openmg the approptiate 
consecutively numbered sealed envelope. Separate treat- 
ment assignments for each hospttal were generated by the 
use of permo!sd block random number sequences. Measure- 
ment of pulmonary artery pressure and pulmoc~ry angiog- 
raphy were regeated immediately after 2 h of treatment: 
follow-up perfusion lung scanning was perfortaed 24 h after 
the start of therapy. 
Pairs of pie- sod post-treatment lung rcass were also 
clusi&. Moderate-sized pulmonary &tbo:int was gwn a 
roded to prevent identtiication of patients, treatment re- 
ceived. participating institutionsand the timmg of the scans 
score of 3 to 6 and generally affected two lobes; massive 
in relation to thrombulytic therapy. The scans were then 
graded asthe proportionafkmgnot perfused. A paneloftwo 
pl;lmonary embolism was given a score of 7 to 9 and at&ted 
nuclear medicine specialists scored each scan in two ways: 
II bv the antarowsterior method used in Urokinase Pulmc- 
the emire tuna. 
nary Embolism Trial (UPET) (6). and 2) by a new segmental 
method (7) that incloded lateral or oblique views. or both, 
I.,. : were not abrained as staadwd practice in IJPET. The 
scant were assesred individually by each panelist uring both 
methods. Periodic meetings oitbe pa.wl were convened by i( 
third nuclear medicine speck&t to resolve by wo~cnsos any 
differences in scoring. 
Pbarmamlc@c regimeas. No patient received concotw 
tam heparin therapy with the thrombolytic agent. ‘The dose 
of If-PA (Activase [Genentech]) was IO0 mg infused through 
a peripheral vein over 2 h @I mdh). The dose of urokinase 
(Abbokinase [Abbott Laboratories]) was modified from the 
dosing p giman of the German hctivxkx Uwkinase Study (5) 
in acute myocardial infarct on, which utilized 3 million U of 
urokinase over 90 mio, of which 1.5 million II war given as 
an initial intravenous bolus it!jection. In our trial, patients 
allxated to urokinase thenpy were premeditated atth 
Complieatimw. Patients were followed up for I4 days to 
determine whether death 31 recurrent ~ulmonw embolism 
had occurred and for 3 days to de&nine whether majot 
bleeding had occurred. Major bleeding was defined as bleed- 
ing that requiied surgical control (such as laparotomy for 
retropetitoneal bleeding) or any intracranial bleeding. As in 
the IJrokinase Pulmonary Embolism Trial (6). we also iden- 
tified ail patients who had a decrease in hematocril of 210 
,wcentage points. 
Coagulation variabkr. Plasma and sxum samples were 
taken tmmediately before therapy and repeated 2 hand 24 h 
after the start of treatment. Blood for plasma tibtinogen was 
drawn into citrdte (I3 mm&liter) wiin aprotiaio (2% IU/m!) 
to prevent in vitro fibrinogenolysis, and it was immediately 
stored on ice. Pirsma wa.s collected from these sampler after 
ccntrifogation and was stored 81 -20°C for up IO 6 weeks. 
Plwna fihrinogcn was measured hy the aodium sulfite pre- 
cipik&n method of Rampling and Gsffney (8) Flbrin and 
fibrinogen degrpdalion products were measured in serum 
samples according to the method of Merskey et al. (9.101. 
Statistical analysli. Thn randomized. lwlrealment 
study began with an millal cohort of 30 patients II5 in each 
treattmcaturm). A” mterimanalyse of thedamon Ihc hrst 30 
patients indicated that a 3UW diffcwce in success rates 
between the two treatment arms could be detected with 80 
patienls (4Olarm) with 80% power and a two-sided level of 
significance of 0.05. Success wan defined as any level of 
improvement in qualitative pulmonary an&graphic scores. 
After the mtenm ana!y$: was complelcd. Ihe study sile was 
set at ‘M patwa~. with Ibe expectal@on lhat data from a1 least 
80 patients would be analyzable. 
Data from the 90 oat~nts who received anv amount of 
drug were arslyzed &th use of SAS stati&4 software. 
TWG pa!ients who were randomized lo lreslmem but re- 
ceived no drug were not mcluded in the analyses. Categoric 
dam analyses were performed with use of chi-square and 
Fisher exact tests (II). Analyses of continuous random 
variables were performed with the Wilcoxon two-sample test 
(121. Confidence inlervols for Ihc differences in proportions 
were calrulated with a normal approximation for the com- 
parison of independent binomial samples (13). Reported p 
values are two-sided. 
Results 
The patients in the &PA and wokmare erwos were well 
malched for baseline charactcrishcs. with no bfatislically 
significant difference in any variable that was assessed 
(Table 1,. Two hours after thesw of therapy. there were no 
significant changes in hemodynamnc venablcs (Table 2). 
EfBeacy. ‘Ihe proportion of patienls showing any im- 
provement on the qualitative pulmonar:f angiogram atsess- 
ments was 19% (33 of 421 ano 61% (30 of 45) for n-PA and 
urokinase. respectively (Table 31. The 95% confidence inter- 
val for the difference in thcsc proportions (n-PA minus 
urokinase) is -6.6% to 30.4% (p = 0.11). With a mu~c 
restrictwe definihon of response that included only modeatc 
or marked improverxot (Fig. 1). the proponion of responses 
was 33% (14 ro 42) and 42% (19 10 45) for n-PA and 
urokinase. respectively (Table 3). The 95% confidence inter- 
val for tile dilTererlce in these proportions (r&PA minus 
urokinase) is -29% to 11.4% (p = 0.39). Patients in the two 
treatment groups were also compared with respect to ihr 
proponion showmg any mqrovemen~ in the quamitativc 
angiographic scores after treatment (Table 4). Patients 
treated with n-PA had a 22.4% improvemen in quantilalive 
scores compared with 17.R% improvement among those 
receiving urokinase. The 95% confidence interval for Ihe 
diiiercnce in ihe proportions (n-PA minus urokinase) is 
-12.3% to 21.3% (p = 0.60). Among the 35 patients with 
masswe pulmonary embolism lpretrea~ment score 271 and 
2-h angiograms. there was no significant difference between 
the effect of n-PA and urokinax (P = 0.74). 
The improvrmrnr in /un~ scan perfrtsion af 24 h was 
similar in Ihc two treatmenl groups whether the ameropo~- 
tenor Ip = 0.?2)2) or segmental Ip = 0.80) scoring mcthod was 
used (Table 51. The interval from the onset of symptoms to 
the ~lart of thrombdytiz lherapy (0 to 5 vs. 6 to I4 days). the 
presence of can&r and a prior history of pulmonary embo- 
lism or deep venous thrombosisdid not influence the eilicacy 
of either n-PA or urokinase. as assessed by the Z-h angio- 
gram or the 24-h perfusion scan. 
Complications. Of the 90 patients who underwent throm- 
bolysis. 1 died within I4 days of treatment. A 78.year old 
woman with a prior myocardial infarction received uroki- 
nose and developed refractory vcn~ricular fibrillation during 
Ihe infusion. Autopsy was not performed and pulmonary 
embolism was considered the cause of death. A B-year old 
woman with metastatic breast carcinoma received n-PA and 
died on the following hospital day. Autopsy revealed extcn- 
sive ia!ravascular adenocarcinoma that had embolized to 
polmonary and hepatic vessels. Although thrombus in the 
deep veins of the right leg was identified, there was so 
cvidcnce of concomitant thromboric pulmonary embolism. 
An II-year old man previoudy in good health received n-PA 
and vomited 75 min after completion of the infusion. He 
became comatose 2.5 h later: computed tomographic sean- 
niog of the head showed a massive subarachnaid aed intro 
cerebral hemorrhage. He died 3 days after treatmerd. 
Two palients rrmed will, urokirrose rrpmurrcrd ~PCIV- 
rem palmonary embolism that was dacumcnled wth new 
perfusion lung scan defects and managed wi,h placemen, of 
an inferior vena cava filter. Another pallen, treated with 
urokinase was considered clinically 10 have recurrent putt 
monary embolism and had a filter placed without undergoing 
repea, lung scanning or pulmcnary angiography. All three of 
these patients were receiving intravenous heparin when 
recurrent pulmonary embolism was diagnosed. 
Two parienrs hnd n nonfatal intmcmnioi hemurriroyu. 
documcmcd bv comouled lomoeraohx scan of the head. 
that resulled in’perm&n, bu, mi&‘ncurologic dnabdoy. A 
72.year old woman with three prior “~~clts” of “vision 
turning black.” but none within the year before acute 
pulmonary embolism. received rt-PA. FM hours after ,er- 
mination of the infusion. aphasia and righ!.Gded weakness 
were noted. She was sent 10 a rehabitirarion facdily for 6 
weeks and was then discharged with minor residual neuro- 
logic deficits. A 67.year old man was transferred Lo :a 
participating hospital for evaluation of delirium and new 
onset grand mal seizures. Ten days after transfer. pulmonary 
embolism was diagnosed and he was enrolled in the study la 
protocol violation because of new onset of sc,zures and new 
mental s,a,us changes). He received umkinase and was 
owed 2 days later to have a new righ, homonymous hemi- 
anopia ,ha, has no, resolved. 
with no pa,ient trearcd woh n-PA tp = U.IM. The Re- 
quency of mqor bleeding complications was similar in both 
,rea,men, groups. Twelve patienls had a hemalocri, dc- 
crease >to percenrage points and It recewed biwd Vans- 
fusmns. Four of the I2 had no obvious source of blecdlng to 
cxplam the decrease in hematacrit. Of the eigb! p~!ieo,s w!h 
an ider,bfied bleeding site. the groin puncture site for pulmo- 
nary angiography accounted for the decreased hematocFit in 
seven pabents and an onsuspected abdominal aoFlic aneu- 
rysm iha, ruptured accounted for the decrease in one pa- 
tin,: Lhis dncurv,m was later wccessfully waired. 
Coaautatioa &tabte% Nadir fibrin&n l&r were ab- 
served at 2 h after inrtzation of thrombolytic therapy and 
exceeded IW mgidl in all pal&Is. The difference between 
the nadir leve! and the baseline plasma fibrinogen level 
(Table 7) was no, sigmficantly different between ,he ,wo 
Lreatmen, groups tp = 0.43). Greater than avenge percent 
decreases m plasma fibrinogen did not identify patients with 
major bleeding. There was no significant difference in fibrin- 
ogen degradation products between treatment groups (p = 
0.641. 
Discussion 
Reeombinan, human tissue-type plarminogen xtivatorand 
urokinase. These agents are swine proteases that have 
similar structural and caralytic propenies (14). We found 
that a 2-h infusion of IW mg of n-PA or 3 milbon U of 
umkinase provided comparable e5cacy and safety. The two 
aeents lvsed thmmbw raoidlv and had a similar likelihood of . . 
causing hemorrhage. Quantitative angiographic ~ssessmen, 
a, 2 h without controlling for baseline values revealed a 
statistically nonsignificant trend favonng &PA over or&i- 
nase (p = 0.16). This trend was also seen wth the qualitative 
angiogrdphic assessment (which evaluated change relative to 
baseline at 2 h) sod was also no, statistically agn,ficanr tp = 
0. I I). However, vfith contml for baseline values. the quan- 
titative anglographic a~sessmenc a, 2 h showed no trend 
favoring rl-PA and differences between resul,s with Ihe two 
agents were not statistically significant (p = 0.60). The 
amties. Rtghi’pnd. Repcal angiogm 
immediately after administration 01 uroki- 
magnitude of the observed difference between r&PA and 
urokinase in the quantitative angiographic asscss~?~en! con- 
trolling for baseline values would require a I.ZSO@ient 
study to detect a statistically significant ddference between 
treatments with 10% power and a two-sided p value of 0.05. 
The improvement in perfusion lung scans at 24 b WBS 
viaaNy identical in both groups. 
Chsra&lirtier of the novel uroddnase dosing regimen. 
When we compare the urokinase resulls in our current and 
previous (I) trials. lhe novel 2-h urokinase regimen appears 
to act more rapidly and 10 be safer than the 24-h resimen; 
66% of patient; de&nstmted angiogmphic improver& at 
2 h compared with 48% who attained this end paint in our 
previous study. Marked or moderate improvement with 
urokinase occurred in 42% of ontients who received 3 million 
U/2 h compared with 13% W&I received an average weight- 
adjusted dose of 1 million U/2 h in the previous xudy. Lung 
scan reperfusion 24 h afler initialion of urokinare was simiiar 
in Ihe two trials. even though the Wal amount of drug 
administered was much less in Ihe current study 0 million U 
versus an average of 7.5 million Ul. The frequency of a 
>I&point decrease in hematocnt was reduced from 48% of 
patients with the 24-h regmten to 6.>% with the 2-h regmen. 
The fixed 2-h dosing regimen of urokinase was much 
more maoagedble than the previously administered wght- 
adjusted 24-h infusion. With this novel dosing schedule. only 
40% as much urokinase was utilized, resulting in a substan- 
tial reduction in cost. However, cwn with aggrescive triple 
drug premeditation. allergic reactions occurred /ir 17% :cm- 
pared with 26% of patienls who received urokinase m rhe 
prior study. Theoretically, the ongoing development oi 
rtwmbinant umkinase should eliminate this moblem 
The success of our urokinase regimeq. m which one third 
of the total dose was given 2s a b&s injection. was 
consistent with the findings in a xdne model of venous 
thrombosis (15) in which a bolus injection/infusion ratio of 
25%/75% of urokinase produced twice as much Iysir as 
either the b&s injection or infusion alone. One can spe;z 
late that the improved resulls with 3 million U/Z h are due m 
pact to saturation with this more concentrated dosing qi- 
men of the recently described plasminogen activate mbibi- 
tar 3 :PzG-:;. 
Prior studies. The results of our previous trial Ill with 
IW m&0 h of n-PA were almost identical to thou of the 
present studv. In these two studies with the same n-PA 
hosing regimen, angiographic evidence of clot lysis al : h 
was obtained in 80% (95% confidence interval 70% to 90%) 
of patients. Lung scan repfrfuston at 24 h was virtually the 
same (28% to 29%) in the t?vo trials. A hematocrit decrease 
of 210 percentage points wds observed in 17% !9S% confi- 
dence interval 8% to 26%) of patienrs treated with It-PA. 
When the frequency of qualitative angiographic improve- 
ment in the two groups treated with n-P.4 is combined and 
then compared with that in the patients receiving the 2-h 
urokinase regimen, the 95% confidence interval for the 
difference in the proportion responding @t-PA minus uroki- 
nase) is -4% to 30% (p = 0.12). lfonly moderate or marked 
an&graphic improvement is considered, the 95% con& 
dence interval for the difference in the prop&on with 
moderate or marked improvement is -19% to 19% (p = 
0.98). 
The lack of reduction in pulmonary artery pressure 
despite successful fibrinolysis in most patients is surprising 
and not readily explained. In our prior open label (16) and 
randomized (I) trials of thrombolysis in pulmonary embo- 
lism, a decrease in pulmonary artery pressure was common 
and usually indicated that therapy succeeded. 
At first glance, our results may appear to conflict with 
those reported by Prewitt et al. (17) in their canine model of 
mdmcnzn~ embo!iwx Thev compared two doses of n-PA 
il and 2 &kg) with t&doses’of umkinase (30,ooO and 
f&o00 U/kg) and found that both n-PA regimens yielded 
more extensive thrombolysis than did either of the uiokinase 
dosing schedules. However, the canine and human fibrin- 
olytic systems may differ and all four of their treatment 
regimens were IS-tin (rather than 2-h) infusions. They 
demonstrated in aprevious study (18) in dogs tharcompress- 
ing the n-PA dosing regimen from 90 to 15 min results in a 
markedly mcreased rate of clot lysis. 
OptimUng safety. Although both 2-h r:pimens caused 
clot I:rsis in most patients, i!nportard bleeding complications 
occurred. The intracranial hemorrhage rate was 3% overall, 
including a I% rate of fatal intracranial bleeding. ‘Ihe lack of 
episodes of intracranial bleeding in our prior studies was 
undoubtedly due to the small number of patients and the play 
of chance. When OUT total experience with thrombolysis in 
pulmonary embolism (I. 16,191 is considered. the overall rate 
of intracranial bleeding is l.6%, including aO.S% rate of fatal 
bleeding. These findings emphasize the need for careful 
ptient selection. 
In I)% of patients in th current trial, the hematocrit 
decreased >lOpercentage p&a. In two tbirdsof cases, this 
decrease was due to bleeding from the pulmonary ang&am 
groin punctlrre site. This observation underscores the need 
for meticulous attention to technical aspects of performing 
pulmonary attgiograms, especially with regard to the initial 
percutaneous puncture of the femoral vein (20). We believe 
that our insis:ence on tbe use of pigtail- or balloon-tipped 
Table 7. Labxaiory Indexes of Rbdoolysis 
It-PA 
catheters fn- pulmonary artery cathdenzaiion was respon. 
sible for the absence of episodes of right venlricular p&o- 
ration and pericardial tamponade. 
Future studies. Expetimenml (21) and clinical (22) re- 
porls suggest hat thmmholysis in pulmonary embolism can 
be achieved with improved safe:y and equivalent el?icacy by 
compressing the infusion into 2 to IS min. adminiswring a 
weigh;-adjusted rather than a fixed dose ofdrug and reducing 
the total dose of r&PA. l-he thecry is that so!uble, cross- 
!ir!x$ Sbriwgen deg:ai.;tiw nmJ~lcts &rived from lysis of 
thrombi causing pulmonary embolism circulate in the plasma 
ard may act as a cofactor similar to fibrin in promoting the 
conversion of p!asminogen to plcsmin when II-PA is infused 
continuously (21). Ilvvpver. after bolus administration, 
n-PA is cleared rapidly and only small amounts of circuIaI- 
ing I.-P4 xc zvailabie to interact with cross-linked fibrino- 
gen degradation pmducts, thereby limiting the potential to 
activale plasma plasminogen and to promote systemic fibrin- 
ogenolysis. 
To rest this hypothesis, we are initiating an international, 
multicenrer. randumind trial comparing bolus injection of 
II-PA (0.6 m&g with a maximal dose of 50 mg dmmistered 
over 15 min) with the IL%mgl2 h dose of R-PA approved by 
the Food and Drug Administration. However. to address lhe 
circumstances under which thrombolysis followed by anti- 
coagulation should be administered for pulmonary embolism 
instead of anticoagulation alone. a future trial wilh a sample 
size of many hundreds of patients will be required to study 
clinical (rather than radiologic imaging) end points such as 
mortality and rxurren~ pulmonary embolism. 
